BriaCell Therapeutics Corp. (BCTX:NASDAQ) closed at $3.71 on October 13, 2026, down 4.13% on the day. The stock trades 74.7% below its 52-week high of $14.68 and 42.7% above its 52-week low of $2.60. Over the past year, it lost 67.5%. BriaCell Therapeutics Corp. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.12% | +4.21% | -3.64% | -16.25% | -67.51% |
In 252 trading sessions since October 13, 2025, BCTX closed higher on 107 days (42%). Its best day was January 13, 2026 (+42.93%) and its worst was January 14, 2026 (-55.49%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 1 time.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
Find more stocks like BCTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.